Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P343 Efficacy of adalimumab in mild-to-moderate inflammatory bowel disease: Real-life data from single-centre experience in the long-term period

ECCO'20 Vienna

Year: 2020
Authors:

F. Akyüz, A. Ormeci, N. Namazova, M. Guzel, A. Abbasgoulizadeh, L. Tahincioğlu, S. Alaskarlı, E. Gürel, E. Bilgin, A. Atasoy, B. Cavus, K. Demir, F. Besısık, S. Kaymakoğlu

Department of Gastroenterology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

P344 Effectiveness of ustekinumab in refractory Crohn’s disease: A real-life experience in a tertiary referral centre

ECCO'20 Vienna

Year: 2020
Authors:

M. Truyens1,2,3, J. Geldof1, G. Dewitte1, E. Glorieus1, P. Hindryckx1,3, T. Lobaton Ortega1,3

1Department of Gastroenterology, University Hospital Ghent, Ghent, Belgium, 2VIB Center for Inflammation Research, Ghent University, Ghent, Belgium, 3IBD Research Unit, Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium

P345 Lack of anti-TNF drugs levels in fistula tissue: A reason for non-response in Crohn’s perianal fistula?

ECCO'20 Vienna

Year: 2020
Authors:

S. Adegbola1, M. Sarafian2, K. Sahnan1, A. Pechlivanis2, R. Phillips1, C. Knowles3, J. Haddow4, J. Warusavitarne1, O. Faiz1, P. Tozer1, E. Holmes2, A. Hart1

1St. Mark’s Hospital, Department of Colorectal Surgery, Harrow, UK, 2Imperial College London, Computational Systems Division, London, UK, 3Queen Mary University of London, Department of Surgery, London, UK, 4The Blizard Institute- Queen Mary University of London, Department of Surgery, London, UK

P346 Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn’s disease patients

ECCO'20 Vienna

Year: 2020
Authors:

C. Liefferinckx1,2, M. Fassin2, D. Thomas3, C. Minsart1,2, A. Cremer1,2, L. Amininejad1, V. Tafciu2, V. Wambacq1, A. Van Gossum1, D. Franchimont1,2

1Department of Gastroenterology, Hôpital Erasme, Brussels, Belgium, 2Laboratory of Experimental Gastroenterology, ULB, Brussels, Belgium, 3Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

P347 Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?

ECCO'20 Vienna

Year: 2020
Authors:

S. Bejar1, G. Bastida Paz1,2, M. Aguas1,2, A. Garrido Marín1, R. Marques3, E. Valero Pérez1, J. del Hoyo Francisco1, L. Tortosa Seguí1, D. Muñoz Gómez1, J.L. Poveda3, P. Nos Mateu1,2

1Department of Gastroenterology, La Fe University Hospital, Valencia, Spain, 2Enfermedad Inflamatoria Intestinal, Instituto de Investigación Sanitaria La Fe de Valencia IIS La Fe, Valencia, Spain, 3Department of Pharmacy, La Fe University Hospital, Valencia, Spain

P348 Clinical outcomes and response predictors of vedolizumab treatment for anti-TNF-failed patients with IBD in Korea: A prospective multicenter cohort study

ECCO'20 Vienna

Year: 2020
Authors:

J. Kim1, H. Yoon2, K.M. Lee3, S.A. Jung4, D.I. Park5, C.H. Choi6, E.S. Kim7, Y. Jung8, C.S. Eun9, T.O. Kim10, S.B. Kang11, Y.S. Kim12, G.S. Seo13, C.K. Lee14, J.P. Im15, S.J. Park16, J.S. Byeon1, S.J. Myung1, S.K. Yang1, B.D. Ye1

1Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea Republic of, 2Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea Republic of, 3Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea Republic of, 4Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea Republic of, 5Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital- Sungkyunkwan University School of Medicine, Seoul, Korea Republic of, 6Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea Republic of, 7Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea Republic of, 8Division of Gastroenterology, Department of Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea Republic of, 9Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea Republic of, 10Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea Republic of, 11Division of Gastroenterology, Department of Internal Medicine, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, Korea Republic of, 12Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea Republic of, 13Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, Korea Republic of, 14Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea Republic of, 15Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea Republic of, 16Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea Republic of

P349 Infliximab in inflammatory bowel disease: Is premedication necessary?

ECCO'20 Vienna

Year: 2020
Authors:

P. Núñez1, C. Figueroa2, L. Flores2, P. Ibáñez2, U. Kronberg3, J. Lubascher2, G. Pizarro2, R. Quera2, D. Simian2

1Gastroenterology Department, San Juan de Dios Hospital, IBD Fellow Clínica Las Condes, Santiago, Chile, 2Clínica Las Condes, Gastroenterology Department, Inflammatory Bowel Disease Program, Santiago, Chile, 3Clínica Las Condes, Surgery Department, Colorectal Unit, Inflammatory Bowel Disease Program, Santiago, Chile

P350 Perceptions of faecal microbiota transplantation in patients with ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

U.K. Chauhan1, J. Popov2, M. Kalantar2, M. Wolfe3, P. Moayyedi3, J.K. Marshall3, S. Halder3, S. Kaasalainen4

1Hamilton Health Sciences, Ambulatory Care Program, Hamilton, Canada, 2College of Medicine and Health, University College Cork, Cork, Ireland, 3Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Canada, 4School of Nursing, McMaster University, Hamilton, Canada

P351 Spontaneous intra-abdominal abscesses in Crohn’s disease: The experience of a tertiary centre

ECCO'20 Vienna

Year: 2020
Authors:

T. Pereira Guedes1, P. Sequeira2, L. Freire1, F. Castro-Poças1, A. Rocha3, M. Santos3, I. Pedroto1, P. Lago1

1Department of Gastroenterology, Centro Hospitalar Universitário do Porto, Porto, Portugal, 2Instituto Ciencias Biomédicas Abel Salazar, University of Porto, Porto, Portugal, Department of General Surgery, 3Centro Hospitalar Universitário do Porto, Porto, Portugal

P352 Infliximab-therapy intensification based on endoscopic activity suppresses treatment interruption among patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

Y. Komaki1, S. Kanmura1, K. Yutsudo1, K. Kosuke2, F. Komaki1, A. Tanaka1, N. Nishimata3, Y. Sameshima4, F. Sasaki1, H. Ooi4, K. Tokushige5, Y. Sameshima3, A. Ido1

1Department of Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, 2Department of Gastroenterology, Kagoshima City Hospital, Kagoshima, Japan, 3Department of Gastroenterology, Sameshima Hospital, Kagoshima, Japan, 4Department of Gastroenterology, Idzuro Imamura Hospital, Kagoshima, Japan, 5Department of Gastroenterology, Kagoshima Kouseiren Hospital, Kagoshima, Japan

P353 Assessing compliance to screening for infectious diseases and vaccination in patients newly diagnosed with inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

R. Pringle, A. Assadsangabi

Department of Gastroenterology, Salford Royal Foundation Trust, Manchester, UK

P354 Objectively measured time spent sitting, standing upright, and stepping is associated with disease severity and faecal calprotectin in patients with ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

M. Raman1, J. Vallance2, K. Lyden3, S. Alana4, C. Ohland5, K. McCoy5, S. Kaur1, R. Panaccione1, R. Reimer6, L. Taylor1

1Department of Medicine, University of Calgary, Calgary, Canada, 2Faculty of Health Disciplines, Athabasca University, Athabasca, Canada, 3N/A, KAL Research and Consulting, Denver, USA, 4University of Calgary, Calgary, Canada, 5University of Calgary, Snyder, Calgary, Canada, 6University of Calgary, Department of Kinesiology, Calgary, Canada

P355 Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)

ECCO'20 Vienna

Year: 2020
Authors:

A. Buisson1, M. Fumery2, M. Serrero3, L. Orsat1, S. Nancey4, P. Rivière5, R. Altwegg6, L. Peyrin-Biroulet7, M. Nachury8, X. Hébuterne9, C. Gilletta10, M. Flamant11, S. Viennot12, G. Bouguen13, A. Amiot14, S. Mathieu15, L. Vuitton16, L. Plastaras17, A. Bourreille18, L. Caillo19, F. Goutorbe20, M. Fumery21, G. Pineton de Chambrun6, A. Attar22, X. Roblin23, B. Pereira24, B. Pariente8

1CHU Estaing, Department of Digestive and Hepatobiliary Medicine, Department of Gastroenterology, Clermont-Ferrand, France, 2CHU Amiens, Gastroenterology, Amiens, France, 3CHU Marseille, Gastroenterology, Marseille, France, 4CHU Lyon-Sud, Gastroenterology, Lyon, France, 5CHU Bordeaux, Gastroenterology, Bordeaux, France, 6CHU Montpellier, Gastroenterology, Montpellier, France, 7CHU Nancy, Gastroenterology, Nancy, France, 8CHU Lille, Gastroenterology, Lille, France, 9CHU Nice, Gastroenterology, Nice, France, 10CHU Toulouse, Gastroenterology, Toulouse, France, 11Private practice, Gastroenterology, Nantes, France, 12CHU Caen, Gastroenterology, Caen, France, 13CHU Rennes, Gastroenterology, Rennes, France, 14CHU Créteil, Gastroenterology, Créteil, France, 15Private practice- Pole Sante Republique ELSAN, Gastroenterology, Clermont-ferrand, France, 16CHU Besançon, Gastroenterology, Besançon, France, 17CH Colmar, Gastroenterology, Clermont-Ferrand, France, 18CHU Nantes, Gastroenterology, Nantes, France, 19CHU Nîmes, Gastroenterology, Nîmes, France, 20CH Bayonne, Gastroenterology, Bayonne, France, 21Private practice, Gastroenterology, Amiens, France, 22Private practice, Gastroenterology, Paris, France, 23CHU St Etienne, Gastroenterology, St-Etienne, France, 24CHU, Biostatistics unit, Clermont-Ferrand, France

P356 Infectious events in patients with inflammatory bowel disease: The impact of immunomodulators and tumour necrosis factor antagonist therapy

ECCO'20 Vienna

Year: 2020
Authors:

P. Andersson, P. Karling

Department of Public Health and Clinical Medicine, Umeå University, Medicine, Umeå, Sweden

P357 Importance of stool drug monitoring in anti-TNF-treated patients

ECCO'20 Vienna

Year: 2020
Authors:

P. Bacsur1, K. Szántó1, T. Madácsy1, D. Kata1, T. Ferenci2, M. Rutka1, A. Bálint1, R. Bor1, A. Fábián1, Á. Milassin1, G. Elekes3, Z. Szepes1, F. Nagy1, I. Földesi3, J. Maléth1, K. Farkas1, T. Molnár1

1First Department of Medicine, University of Szeged, Szeged, Hungary, 2Physiological Controls Research Center, Óbuda University,Budapest, Hungary, 3Department of Laboratory Medicine, University of Szeged, Szeged, Hungary

P358 Predictors of response to faecal microbiota transplantation in patients with active ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

A. Singh1, A. Sood1, V. Midha2, R. Mahajan1, N. Bansal3, K. Kaur4, D. Singh3

1Department of Gastroenterology, Dayanand Medical College and Hospital - Ludhiana, Ludhiana, India, 2Department of Medicine, Dayanand Medical College and Hospital - Ludhiana, Ludhiana, India, 3Research and Development Centre, Dayanand Medical College and Hospital - Ludhiana, Ludhiana, India, 4Department of Pharmacology, Dayanand Medical College and Hospital - Ludhiana, Ludhiana, India

P359 Platelet-rich stroma injection (PRS) as a novel surgical treatment of refractory perianal fistulas in Crohn’s disease: A pilot study

ECCO'20 Vienna

Year: 2020
Authors:

J. Arkenbosch1, O. van Ruler2, R.S. Dwarkasing3, W.R. Schouten2, A.C. de Vries1, E.J.R. de Graaf2, C.J. van der Woude1

1Department of Gastroenterology, Erasmus MC, Rotterdam, The Netherlands, 2Department of Surgery, IJsselland Hospital, Capelle a/d IJssel, The Netherlands, 3Department of Radiology, Erasmus MC, Rotterdam, The Netherlands

P360 Safety and clinical efficacy of double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicentre study

ECCO'20 Vienna

Year: 2020
Authors:

S. Mazza1, A. Fascì1, V. Casini2, C. Ricci3, F. Munari3, L. Pirola4, C. Girelli5, G. Lupinacci6, L. Pastorelli7, F. Cavallaro7, N. Piazza O’Sed7, L. Ferraris8, A. Colucci8, A. Amato9, V. Maurizio1,10, G. Fiorino11, F. Caprioli1,10

1Fondazione IRCCS Cà Granda- Ospedale Policlinico di Milano, Gastroenterology and Endoscopy Unit, Milan, Italy, 2ASST Bergamo Est – Ospedale di Seriate, Unità Operativa di Gastroenterologia, Seriate, Italy, 3ASST degli Spedali Civili di Brescia, Unità Operativa di Gastroenterologia, Brescia, Italy, 4ASST Monza − Ospedale San Gerardo di Monza, Unità Operativa di Gastroenterologia, Monza, Italy, 5ASST Valle Olona – Ospedale di Busto Arsizio, Unità Operativa di Medicina I, Busto Arsizio, Italy, 6ASST Crema – Ospedale Maggiore di Crema, Unità Operativa di Gastroenterologia, Crema, Italy, 7Policlinico San Donato, Unità Operativa di Gastroenterologia, San Donato Milanese, Italy, 8ASST Valle Olona – Ospedale di Gallarate, Unità Operativa di Gastroenterologia, Gallarate, Italy, 9Ospedale Valduce di Como, Unità Operativa di Gastroenterologia, Como, Italy, 10University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy, 11Istituto Clinico Humanitas, IBD Center, Rozzano, Italy

P361 The effect of immunomodulators and other factors on the persistence of biological agents for Crohn’s disease and ulcerative colitis: data from the Australian population-based registry

ECCO'20 Vienna

Year: 2020
Authors:

Y. Ko1,2, S. Paramsothy1,2, R. Leong1,2

1Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, Australia, 2Concord Clinical School, University of Sydney, Sydney, Australia

P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC)

ECCO'20 Vienna

Year: 2020
Authors:

C. Liefferinckx1, P. Bossuyt2, D. Thomas3, J.F. Rahier4, E. Louis5, F. Baert6, P. Dewint7,8, L. Pouillon2, G. Lambrecht9, S. Vermeire10, D. Franchimont1, of Belgian Inflammatory Bowel Disease Research and Development (BIRD)

1Department of Gastroenterology, Hôpital Erasme, Brussels, Belgium, 2Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, 3Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 4Department of Gastroenterology, CHU UCL Namur, Yvoir, Belgium, 5Department of Gastroenterology, Centre Hospitalier Universitaire Sart-Tilman, Liège, Belgium, 6Department of Gastroenterology, AZ Delta, Roeselare, Belgium, 7Department of Gastroenterology, AZ Maria Middelares, Gent, Belgium, 8Department of Gastroenterology, UZ Antwerp, Antwerp, Belgium, 9Department of Gastroenterology, AZ Damian, Oostende, Belgium, 10Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium